Plozasiran

Summary

Plozasiran (CHEMBL6068438) is a phase-3 clinical-stage oligonucleotide; indicated across 3 conditions including hypertriglyceridemia and familial lipoprotein lipase deficiency.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Oligonucleotide
• Indications: 3 conditions
• Clinical trials: 8

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL6068438
Name	Plozasiran
Type	Oligonucleotide
Max phase	3

Also known as: ADS-005, ADS-005 FREE ACID, Plozasiran, PLOZASIRAN

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
hypertriglyceridemia	1	MONDO:0005347	EFO:0004211
familial lipoprotein lipase deficiency	1	MONDO:0009387	MONDO:0009387

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 8.

Phase distribution

Phase	Trials
PHASE3	7
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05089084	PHASE3	ACTIVE_NOT_RECRUITING	Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)
NCT06347003	PHASE3	ACTIVE_NOT_RECRUITING	Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia
NCT06347016	PHASE3	ACTIVE_NOT_RECRUITING	Study of Plozasiran in Adults With Severe Hypertriglyceridemia
NCT06347133	PHASE3	ACTIVE_NOT_RECRUITING	Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia
NCT06822790	PHASE3	RECRUITING	Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
NCT06880770	PHASE3	RECRUITING	Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis
NCT05902598	PHASE3	COMPLETED	A Phase 3 Study of ARO-APOC3 / VSA001 / SAR449124 (Plozasiran) in Chinese Adults With Familial Chylomicronemia Syndrome
NCT06796426	Not specified	AVAILABLE	Treatment Protocol of Plozasiran in Adults With High-Risk Severe Hypertriglyceridemia (SHTG) and in Adults and Adolescents With FCS

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).